PPIG and Cognitive impairment: With increased risk of hospitalization, cognitive impairment, and mortality as risks from anticholinergic drug use, improved understanding of sex, age, and genomic testing of CYP isozymes may be indicated to reduce serious anticholinergic adverse events.